An Evaluation of the Clinical Utility and Safety of the Visant Medical Canalicular Plug

Prospective Multicenter, Randomized, Double-Masked, Controlled Trial to Evaluate Clinical Utility and Safety of the Visant Medical Canalicular Device in Subjects Who Are Candidates for Occlusion With Punctal or Canalicular Plugs

This study is designed to evaluate the clinical utility and safety of the Visant Medical Canalicular Plug compared to a commercially available canalicular plug.

Study Overview

• Status: Completed
• Conditions: Dry Eye
• Intervention / Treatment: Device: Visant Medical Canalicular Plug; Device: Commercially available canalicular plug

Detailed Description

The objective of this study is to evaluate the clinical utility and safety of the Visant Medical Canalicular Plug compared to a commercially available canalicular plug over 6 months of subject follow-up.

Study subjects who are eligible for enrollment and have provided written informed consent will be randomized in a 2:1 ratio (i.e., 2 subjects randomized to the Visant Medical Canalicular Plug for every 1 subject randomized to a commercially available canalicular plug). All study subjects will be treated bilaterally with plugs placed in the inferior canaliculi.

• Study Type: Interventional
• Enrollment (Actual): 156
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85260
      • Schwartz Laser Eye Center
  • California
    • Newport Beach, California, United States, 92663
      • Eye Research Foundation, Inc.
  • Massachusetts
    • Andover, Massachusetts, United States, 01810
      • Andover Eye Associates
  • Virginia
    • Lynchburg, Virginia, United States, 24502
      • Piedmont Eye, Inc.
    • McLean, Virginia, United States, 22102
      • See Clearly Vision

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 22 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Twenty-two (22) years of age or older
2. BCDVA of 20/40 or better in each eye
3. Both eyes with a baseline Schirmer's test with anesthetic ≤ 10 mm/5 minutes
4. Presence of corneal staining in both eyes in any of the 5 areas defined by the NEI/Industry Workshop Scale
5. Baseline OSDI score of at least 23 with no more than 3 responses of "not applicable"
6. Patent bilateral lacrimal drainage system as demonstrated by punctal irrigation
7. If female, subject must be post-menopausal, medically sterile (e.g hysterectomy, bilateral tubal ligation, bilateral oophorectomy) or have negative urine pregnancy test (UPT) on Day 0 of the study and agree to utilize a medically acceptable form of contraception over the course of the study
8. Willing and able to sign informed consent and HIPAA authorization, follow study instructions, and complete all study visits.

Exclusion Criteria:

1. Use of ophthalmic cyclosporine (Restasis) within 6 months or lifitegrast (Xiidra) within 3 months prior to Day 0 in either eye
2. History of surgical punctal occlusion (e.g., cautery), canalicular infection or canalicular surgery in either eye
3. Corneal transplant in either eye
4. Ocular surgery (such as cataract surgery or LASIK) in either eye within six months of the Baseline Visit
5. A systemic condition or disease not stabilized or judged by the investigator to be incompatible with participation in the study (e.g. current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease)
6. The history or presence of any ocular disorder or condition in either eye that, in the opinion of the investigator, would interfere with the interpretation of the study results (e.g., significant corneal or conjunctival scarring, pterygium or nodular pinguecula; current ocular infection (except mild blepharitis), conjunctivitis or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; history of ocular herpetic infection; evidence of keratoconus; lid or lacrimal cancer
7. Active severe systemic allergy, seasonal allergies, rhinitis or sinusitis requiring treatment (i.e., antihistamines, decongestants, oral or aerosol steroids)
8. Use of steroids, including administration by systemic or topical ocular routes (dermatologic steroids not applied to the eyelids and inhaled steroids are allowed)
9. Participation in a clinical trial during the past 30 days
10. Women who are pregnant, planning a pregnancy, or nursing at study entry

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Visant Medical Canalicular Plug; Bilateral placement of the Visant Canalicular Plug inserted on Day 1	Device: Visant Medical Canalicular Plug; Plug is inserted into the inferior canaliculi and assessed for 6 months
ACTIVE_COMPARATOR: Commercially available canalicular plug; Bilateral placement of commercially available canalicular plug inserted on Day 1	Device: Commercially available canalicular plug; Plug is inserted into the inferior canaliculi and assessed for 6 months

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Mean change in Schirmer's score from baseline to Month 3 compared to commercially available plug	Non-inferiority hypothesis. Higher Score using this continuous variable equates to larger tear film	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of responders achieving improvement from Baseline in Ocular Surface Disease Index (OSDI) score by a Minimal Clinically Important Difference (MCID).	Non-inferiority hypothesis. Scale of 0-100. Lower OSDI score means fewer symptoms.	3 months
Mean change in tear meniscus height from baseline	Null hypothesis of no improvement from baseline. Larger measurement equates to larger tear film.	Month 3
Mean change in OSDI score from baseline	Null hypothesis of no improvement from baseline. Non-inferiority hypothesis. Scale of 0-100. Lower OSDI score means fewer symptoms.	Month 3
Mean change in corneal staining score from baseline (NEI workshop scale)	Null hypothesis of no improvement from baseline. Scale is 0-15. More staining is associated with more severe dry eye.	Month 3
Mean change in tear meniscus height from baseline	Null hypothesis of no improvement from baseline. Larger measurement equates to larger tear film.	Month 6
Mean change in OSDI score from baseline	Null hypothesis of no improvement from baseline. Non-inferiority hypothesis. Scale of 0-100. Lower OSDI score means fewer symptoms.	Month 6
Mean change in corneal staining score from baseline (NEI workshop scale)	Null hypothesis of no improvement from baseline. Scale is 0-15. More staining is associated with more severe dry eye.	Month 6
Mean change in tear break up time from baseline	Null hypothesis of no improvement from baseline. Increased time equates to more stable tear film	Month 3
Mean change in Schirmer score from baseline	Null hypothesis of no improvement from baseline. Higher Score using this continuous variable equates to larger tear film	Month 6
Mean change in tear break up time from baseline	Null hypothesis of no improvement from baseline. Increased time equates to more stable tear film	Month 6

Collaborators and Investigators

• Sponsor: Visant Medical, Inc.
• Investigators: Study Director: Roger Albright, Ora Clinical Research Organization

Study record dates

Study Major Dates

• Study Start (ACTUAL): October 6, 2020
• Primary Completion (ACTUAL): February 9, 2022
• Study Completion (ACTUAL): February 9, 2022

Study Registration Dates

• First Submitted: December 2, 2020
• First Submitted That Met QC Criteria: March 24, 2021
• First Posted (ACTUAL): March 25, 2021

Study Record Updates

• Last Update Posted (ACTUAL): June 6, 2022
• Last Update Submitted That Met QC Criteria: June 2, 2022
• Last Verified: March 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Lacrimal Apparatus Diseases; Dry Eye Syndromes
• Other Study ID Numbers: D-348-CSP

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes